LINCOLN PHARMA Latest Share Price (LINCOLN)
TODAY IN ONE LINE
LINCOLN slipped 0.3% on light volume, in line with Nifty's 0.1% move.
With a market cap of ₹1,239.84 Cr., it trades at a P/E of 12.83. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
LINCOLN PHARMA flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Healthy Operating MarginsOPM is structurally strong at 17.4%
- ●Reasonable ValuationTrading at a moderate P/E of 14.2x
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.01x
- ●Positive Free Cash FlowFCF has been positive for 3 consecutive years
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
No red flags identified
Latest LINCOLN PHARMA News
What changed recently?
Recent events, corporate actions, and announcements.
LINCOLN PHARMA valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for LINCOLN PHARMA, framed against the sector median so the premium or discount is obvious at a glance.
LINCOLN PHARMA trades at a P/E of 12.83× and P/B of 1.63×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
LINCOLN PHARMA technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for LINCOLN PHARMA — derived from the latest tape, not yesterday's close.
LINCOLN PHARMA last traded at ₹620.8 with an intraday range of ₹618–₹631 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹620.80| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 654.53 | +33.73 | +5.43% |
| R3 | 641.53 | +20.73 | +3.34% |
| R2 | 636.27 | +15.47 | +2.49% |
| R1 | 628.53 | +7.73 | +1.25% |
| PIVOT | 623.27 | 2.47 | 0.40% |
| CURRENT | 620.80 | — | — |
| S1 | 615.53 | -5.27 | -0.85% |
| S2 | 610.27 | -10.53 | -1.70% |
| S3 | 602.53 | -18.27 | -2.94% |
| S4 | 589.53 | -31.27 | -5.04% |
LINCOLN is trading Below CPR, indicating Bearishness
CPR is Average
Day's range: ₹618.05–₹631
Trading Inside opening range
LINCOLN PHARMA financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for LINCOLN PHARMA — consolidated or standalone — with margins, YoY growth and key ratios inline.
LINCOLN PHARMA reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹1,239.84 Cr. and reported EPS of ₹18.09.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 623 | 671 ▲ 7.7% |
| Sales Growth YoY %Derived | 7.35% | 7.67% |
| Other Income | 22 | 33 ▲ 48.8% |
| Total Income | 646 | 704 ▲ 9.1% |
| 291 | 311 ▲ 6.8% | |
| Gross ProfitDerived | 332 | 360 ▲ 8.4% |
| Gross Margin %Derived | 53.26% | 53.63% |
| 230 | 262 ▲ 13.8% | |
| EBITDA (Operating Profit)Derived | 101 | 98 ▼ 3.8% |
| OPM %Derived | 16.29% | 14.56% |
| 15 | 16 ▲ 4.9% | |
| Profit Before Tax (PBT) | 109 | 116 ▲ 5.9% |
| 27 | 28 ▲ 3.3% | |
| Effective Tax %Derived | 24.58% | 23.98% |
| Total Profit for Period | 82 | 88 ▲ 6.7% |
| Less: Non-controlling Interests | — | — |
| Net Profit (Owner's PAT)Derived | 82 | 88 ▲ 6.7% |
| Net Profit Margin %Derived | 13.21% | 13.10% |
| PAT Growth YoY %Derived | -11.74% | 6.74% |
| Earnings Per Share (EPS ₹) | 41.11 | 43.88 ▲ 6.7% |
| Diluted Shares Outstanding (Cr) | 2 | 2 ▲ 0.0% |
| Other Comprehensive Income (Net of Tax) | 0 | 2 ▲ 1726.6% |
| Total Expenses (incl. D&A & Interest) | 537 | 589 ▲ 9.8% |
| Material Cost % of RevenueDerived | 34.33% | 35.70% |
| Employee Cost % of RevenueDerived | 18.04% | 18.66% |
| Other Cost % of RevenueDerived | 18.93% | 20.42% |
| Interest Coverage (x)Derived | 47.05x | 82.12x |
| Period | Mar 2018 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|---|---|
| Revenue from Operations | 362 | 472 ▲ 30.6% | 510 ▲ 8.1% | 581 ▲ 13.8% | 623 ▲ 7.4% | 671 ▲ 7.7% | |
| Sales Growth YoY %Derived | — | — | 8.09% | 13.76% | 7.35% | 7.67% | |
| Other Income | 5 | 10 ▲ 83.3% | 22 ▲ 124.8% | 34 ▲ 53.2% | 22 ▼ 34.7% | 33 ▲ 48.8% | |
| Total Income | 367 | 482 ▲ 31.3% | 533 ▲ 10.5% | 615 ▲ 15.4% | 646 ▲ 5.0% | 704 ▲ 9.1% | |
193 | 219 ▲ 13.5% | 241 ▲ 10.4% | 278 ▲ 15.3% | 291 ▲ 4.7% | 311 ▲ 6.8% | ||
| Gross ProfitDerived | 169 | 254 ▲ 49.9% | 269 ▲ 6.1% | 302 ▲ 12.4% | 332 ▲ 9.8% | 360 ▲ 8.4% | |
| Gross Margin %Derived | 46.77% | 53.70% | 52.70% | 52.06% | 53.26% | 53.63% | |
117 | 158 ▲ 35.3% | 180 ▲ 13.7% | 202 ▲ 12.6% | 230 ▲ 13.9% | 262 ▲ 13.8% | ||
| EBITDA (Operating Profit)Derived | 52 | 95 ▲ 82.5% | 89 ▼ 6.6% | 100 ▲ 12.0% | 101 ▲ 1.6% | 98 ▼ 3.8% | |
| OPM %Derived | 14.47% | 20.22% | 17.48% | 17.21% | 16.29% | 14.56% | |
12 | 10 ▼ 17.2% | 11 ▲ 17.4% | 12 ▲ 8.0% | 15 ▲ 22.3% | 16 ▲ 4.9% | ||
| Profit Before Tax (PBT) | 46 | 96 ▲ 107.4% | 100 ▲ 4.7% | 122 ▲ 21.7% | 109 ▼ 10.7% | 116 ▲ 5.9% | |
12 | 27 ▲ 129.2% | 28 ▲ 3.7% | 29 ▲ 4.9% | 27 ▼ 7.2% | 28 ▲ 3.3% | ||
| Effective Tax %Derived | 25.08% | 27.71% | 27.45% | 23.67% | 24.58% | 23.98% | |
| Total Profit for Period | 35 | 69 ▲ 100.2% | 73 ▲ 5.1% | 93 ▲ 28.0% | 82 ▼ 11.7% | 88 ▲ 6.7% | |
| Less: Non-controlling Interests | 0 | — ▼ 100.0% | — | — | — | — | |
| Net Profit (Owner's PAT)Derived | 35 | 69 ▲ 100.3% | 73 ▲ 5.1% | 93 ▲ 28.0% | 82 ▼ 11.7% | 88 ▲ 6.7% | |
| Net Profit Margin %Derived | 9.57% | 14.69% | 14.29% | 16.07% | 13.21% | 13.10% | |
| PAT Growth YoY %Derived | — | — | 5.11% | 27.99% | -11.74% | 6.74% | |
| Earnings Per Share (EPS ₹) | 17.31 | 34.63 ▲ 100.1% | 36.40 ▲ 5.1% | 46.58 ▲ 28.0% | 41.11 ▼ 11.7% | 43.88 ▲ 6.7% | |
| Diluted Shares Outstanding (Cr) | 2 | 2 ▲ 0.1% | 2 ▲ 0.0% | 2 ▲ 0.0% | 2 ▲ 0.0% | 2 ▲ 0.0% | |
| Other Comprehensive Income (Net of Tax) | 0 | 0 ▲ 31.7% | -0 ▼ 329.1% | 0 ▲ 120.5% | 0 ▲ 50.1% | 2 ▲ 1726.6% | |
| Total Expenses (incl. D&A & Interest) | 321 | 386 ▲ 20.4% | 432 ▲ 11.9% | 493 ▲ 14.0% | 537 ▲ 8.9% | 589 ▲ 9.8% | |
| Material Cost % of RevenueDerived | 25.32% | 33.57% | 34.68% | 34.64% | 34.33% | 35.70% | |
| Employee Cost % of RevenueDerived | 14.14% | 14.93% | 18.26% | 17.72% | 18.04% | 18.66% | |
| Other Cost % of RevenueDerived | 18.16% | 18.55% | 16.96% | 17.12% | 18.93% | 20.42% | |
| Interest Coverage (x)Derived | 8.54x | 60.22x | 39.43x | 60.95x | 47.05x | 82.12x |
LINCOLN PHARMA segment analysis : revenue and profit mix.
Disclosed business segments at LINCOLN PHARMA with their share of revenue and profit, switchable between consolidated and standalone reporting.
LINCOLN PHARMA discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for LINCOLN PHARMA.
Our AI distills the core fundamental drivers supporting LINCOLN PHARMA, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
LINCOLN PHARMA's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Zero debt with D/E ratio 0.0001x provides exceptional financial flexibility and stability.
Operating margin 12.40% demonstrates consistent operational efficiency in pharmaceutical manufacturing.
Latest quarterly EPS grew 0.5% YoY, indicating steady earnings momentum despite modest growth.
Export network spans 60 countries across multiple continents, diversifying revenue streams significantly.
P/E ratio 14.18x trades substantially below pharmaceutical sector median, suggesting valuation upside.
Key Risks.
Market cap ₹0.01 LCr severely limits institutional investor participation and trading liquidity.
Dividend yield 0.30% unattractive for income-focused investors seeking regular returns.
ROE 11.60% and ROCE 11.97% lag peer benchmarks, indicating suboptimal capital efficiency.
TTM revenue growth 11.4% modest relative to faster-growing generic pharmaceutical competitors.
52-week price return flat at 0% despite earnings growth signals weak investor momentum.
Flip Conditions.
Valuation risk. a P/E above 17 would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Return-quality risk. ROE below 8% would indicate weaker capital compounding.
Income thesis breaks if the dividend is cut or yield falls below 0.15%.
LINCOLN PHARMA peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — LINCOLN PHARMA is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
LINCOLN PHARMA chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for LINCOLN PHARMA — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
LINCOLN PHARMA delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for LINCOLN PHARMA over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in LINCOLN PHARMA stood at 62.4% of traded volume, against a 20-day average of 52.6%.
LINCOLN PHARMA announcements: results, concalls, ratings, M&A.
Filings LINCOLN PHARMA sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
LINCOLN PHARMA files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 52 documents below.
Updates
Lincoln Pharmaceuticals Limited has informed the Exchange Intimation regarding dispatch of physical communication to the Shareholders who have not…
Shareholders meeting
Lincoln Pharmaceuticals Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 30, 2026.
Record Date
Lincoln Pharmaceuticals Limited has informed the Exchange that Record date for the purpose of Dividend is 11-Sep-2026.
Copy of Newspaper Publication
Lincoln Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication regarding the 32nd Annual General Meeting of the…
Copy of Newspaper Publication
Lincoln Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication
Investor decks & rating reports.
LINCOLN PHARMA dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue LINCOLN PHARMA has declared, sequenced by announce and record date.
LINCOLN PHARMA corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About LINCOLN PHARMA: business, sector, key facts.
What LINCOLN PHARMA does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
LINCOLN PHARMA operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: LINCOLN, BSE: 531633.
Lincoln Pharmaceuticals Limited is an Indian pharmaceutical company primarily involved in the manufacturing and trading of a wide range of pharmaceutical products within India and for export to approximately 60 countries globally. These countries span several continents, including Europe, Canada, Latin and North America, Africa, the Asia Pacific region, and Southeast Asia, demonstrating a significant international presence for the company.
Their product portfolio is extensive, covering various therapeutic areas. This includes common ailments like colds, as well as more specialized treatments for conditions such as ear, nose, and throat (ENT) issues, pain, gastrointestinal problems, malaria, fungal infections, and skin conditions. Beyond this, Lincoln Pharmaceuticals offers products addressing more serious health concerns, including diabetes, hypertension (high blood pressure), gynecological issues, cardiovascular diseases (cardio and CNS), respiratory problems, and dyslipidemia (high cholesterol).
A key aspect of their business model is the production and distribution of branded generics. This means they produce medications that are similar to brand-name drugs but are sold under their own brand name at typically lower prices. This strategy likely caters to both domestic and international markets where cost-effectiveness is a crucial factor in accessing essential medicines. The breadth of their therapeutic areas, coupled with their export-oriented approach, suggests a strategy aimed at capturing a significant share of both the domestic and international pharmaceutical markets.
Established in 1979 and headquartered in Ahmedabad, India, Lincoln Pharmaceuticals has a history spanning several decades in the pharmaceutical industry. Their longevity and continued expansion into international markets indicate successful navigation of the competitive landscape and a robust business strategy that effectively combines manufacturing capabilities with a well-defined global distribution network. The company's diversified product portfolio positions it to address a broad spectrum of healthcare needs across various geographic regions.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- AAREY DRUGS & PHARM (AAREYDRUGS) Share PricePeer
- AARTI DRUGS (AARTIDRUGS) Share PricePeer
- AARTI PHARMALABS (AARTIPHARM) Share PricePeer
- AJANTA PHARMA (AJANTPHARM) Share PricePeer
- AKUMS DRUGS AND PHARMA L (AKUMS) Share PricePeer
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about LINCOLN PHARMA (LINCOLN).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of LINCOLN PHARMA (LINCOLN)?
The current share price of LINCOLN PHARMA (LINCOLN) is ₹620.80. Today, the stock has declined by ₹1.85 (0.3%), trading in a range of ₹618.00 to ₹631.00. The stock opened at ₹627.00 with a trading volume of 29,091 shares.
02Is LINCOLN PHARMA stock a good investment for long-term?
LINCOLN PHARMA can be considered for long-term investment based on several factors. The company has a market capitalization of ₹1,239.84 Cr., P/E ratio of 12.83, ROE of 11.6%, and ROCE of 11.97%. The dividend yield stands at 0.3%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of LINCOLN PHARMA stock?
The 52-week high price of LINCOLN PHARMA (LINCOLN) is ₹770.00, while the 52-week low is ₹440.00. Currently trading at ₹620.80, the stock is 41.09% above its 52-week low and 19.38% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy LINCOLN PHARMA stock at the current price?
Whether to buy LINCOLN PHARMA stock at ₹620.80 depends on multiple factors. The stock is currently trading with a P/E ratio of 12.83 and P/B ratio of 1.63. Today's performance shows a loss of 0.3%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of LINCOLN PHARMA and when is the next dividend?
LINCOLN PHARMA offers a dividend yield of 0.3%, which means for every ₹100 invested at the current price of ₹620.80, you can expect to receive approximately ₹0.30 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of LINCOLN PHARMA?
LINCOLN PHARMA's key financial metrics include: P/E Ratio: 12.83, P/B Ratio: 1.63, ROE: 11.6%, ROCE: 11.97%, Dividend Yield: 0.3%, EPS: ₹18.09, Book Value: ₹378.25, and Debt-to-Equity: 0.01. The company's market cap stands at ₹1,239.84 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is LINCOLN PHARMA stock performing today in the market?
LINCOLN PHARMA stock opened at ₹627.00 and is currently trading at ₹620.80, showing a decline of ₹1.85 (0.3%). The intraday high is ₹631.00 and low is ₹618.00. The trading volume stands at 29,091 shares, indicating moderate market participation today.
08What is the P/E ratio of LINCOLN PHARMA and what does it indicate?
LINCOLN PHARMA has a Price-to-Earnings (P/E) ratio of 12.83, which means investors are willing to pay 12.83 for every ₹1 of earnings. With an EPS of ₹18.09, this P/E ratio suggests the stock may be undervalued or facing growth challenges. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about LINCOLN PHARMA (LINCOLN) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.